Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ebglyss is a prescription monoclonal antibody containing lebrikizumab-lbkz. It is an interleukin-13 antagonist approved for moderate to severe atopic dermatitis in adults and pediatric patients age 12 and older who weigh at least 40 kg when topical prescription therapies do not adequately control the disease or are not advisable.
read more about ebglyss ...Lebrikizumab-lbkz binds interleukin-13 and inhibits signaling through the IL-4 receptor alpha and IL-13 receptor alpha 1 complex. IL-13 contributes to type 2 inflammation involved in atopic dermatitis. Blocking this signaling reduces IL-13-induced inflammatory responses.
Ebglyss is used for moderate to severe atopic dermatitis in adults and patients age 12 and older who weigh at least 40 kg. It can be used with or without topical corticosteroids. Age-appropriate vaccinations are completed before treatment, and live vaccines are avoided immediately before and during therapy.
The starting dose is 500 mg as two 250 mg injections at week 0 and week 2. Treatment then continues with 250 mg every two weeks until week 16 or later when adequate clinical response is reached. Maintenance treatment is 250 mg every four weeks or every eight weeks under the June 2026 label.
Serious concerns include hypersensitivity reactions such as angioedema and urticaria, conjunctivitis, keratitis, and parasitic infections. Pre-existing helminth infections are treated before Ebglyss begins. If a helminth infection does not respond to treatment during therapy, Ebglyss is stopped until the infection resolves.
Ebglyss treats moderate to severe atopic dermatitis under age, weight, and prior topical-treatment criteria.
Current labeling includes adults and patients age 12 and older who weigh at least 40 kg.
Patients receive 500 mg at week 0 and week 2, followed by 250 mg every two weeks initially.
After adequate clinical response, maintenance dosing is 250 mg every four weeks or every eight weeks.
DailyMed - EBGLYSS (lebrikizumab-lbkz) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f. Date Accessed September 29, 2026.
EBGLYSS (lebrikizumab-lbkz) Prescribing Information. Eli Lilly and Company. https://uspl.lilly.com/ebglyss/ebglyss.html?s=pi. Date Accessed September 29, 2026.
FDALabel - EBGLYSS (lebrikizumab-lbkz). https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/407373. Date Accessed September 29, 2026.
Lebrikizumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lebrikizumab. Date Accessed September 29, 2026.
Lebrikizumab-lbkz Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a624064.html. Date Accessed September 29, 2026.